Interní Med. 2014; 16(5): 179-183
The treatment of hypercholesterolemia by PCSK9 inhibitors
- III. interní gerontometabolická klinika LF UK a FN, Hradec Králové
Proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism because of its pivotal role
in the degradation of the LDL receptor. In recent years, both in vitro and in vivo studies have greatly supplemented our understanding
of the role of PCSK9 in human biology. As PCSK9 has emerged as a novel target for LDL-C lowering therapy, being discovered in 2003,
recent developments in inhibition of PCSK9 are reviewed. Initial data from investigations of PCSK9 inhibition in humans are promising
and indicate that PCSK9 inhibition may be a viable new therapeutic option for the treatment of dyslipidemia and associated cardiovascular
diseases.
Keywords: cholesterol, drug therapy, LDL cholesterol metabolism, proprotein convertase subtilisin/kexin type 9
Published: November 1, 2014 Show citation
References
- Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver ChR et al. Tre metabolic and molecular bases of inherited disease. 8th ed. New York, McGraw-Hill, inc. 2001; 3. Vol: 2863-2914.
- Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156.
Go to original source... 
Go to PubMed... - Seidah NG, Prat A. The biology and therapeutic targeting of the preprotein convertases. Nat Rev Drug Discov 2012; 11: 367-383. Go to original source... Go to PubMed...
- Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116: 2995e3005. Go to original source...
- Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006; 15: 1551e8. Go to original source... Go to PubMed...
- Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem 2009; 284: 28856e64. Go to original source... Go to PubMed...